NCT00818649View on ClinicalTrials.gov

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

bortezomib

1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle

DRUG

vorinostat

400 mg orally (po) every day on days 1-14 of a 21 day cycle

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER